Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose Ketamine for Acute Pain and Depressive Symptoms in the ED
NCT03436121Phase 3Withdrawn
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ketamine in acute pain, major depressive disorder (MDD). Planned start Dec 2019; status: withdrawn.
02
Drugs
ketamine
03
Conditions
acute painmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03436121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436121.